Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript
SEARCH
Search

Most cited

Page Path
HOME > Browse articles > Most cited
29 Most cited
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Special Articles
Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction
Eui-Soon Kim, Jong-Chan Youn, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2020;2(4):113-133.   Published online October 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e17
  • 8,182 View
  • 123 Download
  • 12 Citations
Abstract PDF
Heart failure (HF) is an important cardiovascular disease because of the increasing prevalence, high morbidity and mortality, and rapid expansion of health care costs. Over the past decades, efforts have been made to modify the prognosis of patients with HF. Regarding HF with reduced ejection fraction (HFrEF), several drugs have shown to improve mortality and morbidity, based on large-scale randomized controlled trials, leading to a critical paradigm shift in its pharmacological treatment. The paradigm of HFrEF pathophysiology has shifted from cardiorenal disease to hemodynamic changes, and neurohormonal activation is currently considered the prime pathophysiological mechanism of HFrEF. This review summarizes evidence on the pharmacological management of HFrEF derived from major randomized controlled trials, which have accomplished improvements in survival benefits.

Citations

Citations to this article as recorded by  
  • Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea
    Eui-Soon Kim, Sun-Kyeong Park, Jong-Chan Youn, Hye Sun Lee, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Jin Joo Park, Dong-Ju Choi,
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea
    Eui-Soon Kim, Sun-Kyeong Park, Daniel Sung-ho Cho, Jong-Chan Youn, Hye Sun Lee, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Jin Joo
    American Journal of Cardiovascular Drugs.2024; 24(2): 313.     CrossRef
  • Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
    Jong-Chan Youn, Darae Kim, Jae Yeong Cho, Dong-Hyuk Cho, Sang Min Park, Mi-Hyang Jung, Junho Hyun, Hyun-Jai Cho, Seong-Mi Park, Jin-Oh Choi, Wook-Jin Chung, Byung-Su Yoo, Seok-Min Kang
    Korean Circulation Journal.2023; 53(4): 217.     CrossRef
  • Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
    Jong-Chan Youn, Darae Kim, Jae Yeong Cho, Dong-Hyuk Cho, Sang Min Park, Mi-Hyang Jung, Junho Hyun, Hyun-Jai Cho, Seong-Mi Park, Jin-Oh Choi, Wook-Jin Chung, Byung-Su Yoo, Seok-Min Kang
    International Journal of Heart Failure.2023; 5(2): 66.     CrossRef
  • Post-transplantation outcomes of sensitized patients receiving durable mechanical circulatory support
    Jong-Chan Youn, Xiaohai Zhang, Keith Nishihara, In-Cheol Kim, Sang Hong Baek, Osamu Seguchi, Evan P. Kransdorf, David H. Chang, Michelle M. Kittleson, Jignesh K. Patel, Robert M. Cole, Jaime D. Moriguchi, Danny Ramzy, Fardad Esmailian, Jon A. Kobashigawa
    The Journal of Heart and Lung Transplantation.2022; 41(3): 365.     CrossRef
  • Treatment of heart failure with a preserved ejection fraction
    Yuran Ahn, Jong-Chan Youn
    Journal of the Korean Medical Association.2022; 65(1): 18.     CrossRef
  • Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
    Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn
    Diagnostics.2022; 12(3): 627.     CrossRef
  • Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
    In-Cheol Kim, Jong-Chan Youn, Se Yong Jang, Sang Eun Lee, Hyun-Jai Cho, Jin-Oh Choi, Ju-Hee Lee, Kyung-Hee Kim, Sun Hwa Lee, Kye Hun Kim, Jong Min Lee, Byung-Su Yoo, Byung-Su Yoo, Se Yong Jang, Jong Min Lee, In-Cheol Kim, Jin-Oh Choi, Hyun-Jai Cho, Sang E
    Scientific Reports.2022;[Epub]     CrossRef
  • A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study
    Kyung An Kim, Eui-Soon Kim, Jong-Chan Youn, Hye Sun Lee, Soyoung Jeon, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Dong-Ju Choi, Byu
    European Heart Journal - Cardiovascular Pharmacotherapy.2022; 8(6): 587.     CrossRef
  • Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation
    Jong-Chan Youn, Darae Kim, In-Cheol Kim, Hye Sun Lee, Jin-Oh Choi, Eun-Seok Jeon, Keith Nishihara, Evan P. Kransdorf, David H. Chang, Michelle M. Kittleson, Jignesh K. Patel, Danny Ramzy, Fardad Esmailian, Jon A. Kobashigawa
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Pathophysiology of Heart Failure with Preserved Ejection Fraction
    Jong-Chan Youn, Yuran Ahn, Hae Ok Jung
    Heart Failure Clinics.2021; 17(3): 327.     CrossRef
  • Heart failure risk in younger adults needing more attention
    Jong-Chan Youn, Sang Hong Baek
    International Journal of Cardiology.2021; 344: 135.     CrossRef
Competing Risk Model in Survival Analysis
Yena Jeon, Won Kee Lee
Cardiovasc Prev Pharmacother. 2020;2(3):77-84.   Published online July 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e11
  • 5,998 View
  • 369 Download
  • 3 Citations
Abstract PDF
Survival analysis is primarily used to identify the time-to-event for events of interest. However, there subjects may undergo several outcomes; competing risks occur when other events may affect the incidence rate of the event of interest. In the presence of competing risks, traditional survival analysis such as the Kaplan-Meier method or the Cox proportional hazard regression introduces biases into the estimation of survival probability. In this review, we discuss several methods that can be used to consider competing risks in survival analysis: the cumulative incidence function, the cause-specific hazard function, and Fine and Gray's Subdistribution hazard function. We also provide a guide for conducting competing risk analysis using SAS with the bone marrow transplantation dataset presented by Klein and Moeschberger (1997).

Citations

Citations to this article as recorded by  
  • People with genetic kidney diseases on kidney replacement therapy have different clinical outcomes compared to people with other kidney diseases
    Helen Y. Han, Venkat Vangaveti, Matthew Jose, Monica Suet Ying Ng, Andrew John Mallett
    Scientific Reports.2024;[Epub]     CrossRef
  • Factor modification in the association between high-density lipoprotein cholesterol and liver cancer risk in a nationwide cohort
    Su Youn Nam, Junwoo Jo, Won Kee Lee, Chang Min Cho
    International Journal of Epidemiology.2024;[Epub]     CrossRef
  • Standard Survival Analysis Can Overestimate Incidence and Risk Factors of Event of Interest in a Prospective Cohort Study with Considerable Attrition: The Case of a Suicide High-Risk Cohort
    Min Ji Kim, Maengseok Noh, Jieun Yoo, Seung Yeon Jeon, Jungjoon Moon, Seong Jin Cho, Sang Yeol Lee, Se-Hoon Shim, Shin Gyeom Kim, Won Sub Kang, Min-Hyuk Kim, Christopher Hyung Keun Park, Daun Shin, Sang Jin Rhee, Jeong Hun Yang, Yong-Min Ahn, Weon-Young L
    SSRN Electronic Journal .2022;[Epub]     CrossRef
Review Articles
Recent Technology-Driven Advancements in Cardiovascular Disease Prevention
Jisan Lee, Hun-Sung Kim, Dai-Jin Kim
Cardiovasc Prev Pharmacother. 2019;1(2):43-49.   Published online October 31, 2019
DOI: https://doi.org/10.36011/cpp.2019.1.e7
  • 4,680 View
  • 18 Download
  • 3 Citations
Abstract PDFSupplementary Material
Recent dramatic developments in information and communication technologies have been widely applied to medicine and healthcare. In particular, biometric sensors in wearable devices linked to smartphones are collecting vast amounts of personal health data. To best use these accumulated data, personalized healthcare services are emerging, and digital platforms are being developed and studied to enable data integration and analysis. The implementation of biometric sensors and smartphones for cardiovascular and cerebrovascular healthcare emerged from the research on the feasibility and efficacy of the devices in the clinical environment. It is important to understand the recent research trends in data generation, integration, and application to prevent and treat cardiovascular and cerebrovascular diseases. This paper describes these recent developments in treating cardiovascular diseases.

Citations

Citations to this article as recorded by  
  • Sex- and Age-Specific Trends in Cardiovascular Health in Korea, 2007–2018
    So Mi Jemma Cho, Hokyou Lee, Hyeon Chang Kim
    Korean Circulation Journal.2021; 51(11): 922.     CrossRef
  • Lack of Acceptance of Digital Healthcare in the Medical Market: Addressing Old Problems Raised by Various Clinical Professionals and Developing Possible Solutions
    Jong Il Park, Hwa Young Lee, Hyunah Kim, Jisan Lee, Jiwon Shinn, Hun-Sung Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Lessons from Use of Continuous Glucose Monitoring Systems in Digital Healthcare
    Hun-Sung Kim, Kun-Ho Yoon
    Endocrinology and Metabolism.2020; 35(3): 541.     CrossRef
Adverse effects of statin therapy and their treatment
Dae Young Cheon, Sang-Ho Jo
Cardiovasc Prev Pharmacother. 2022;4(1):1-6.   Published online January 20, 2022
DOI: https://doi.org/10.36011/cpp.2022.4.e4
  • 11,755 View
  • 474 Download
  • 2 Citations
Abstract PDF
Statins are one of the most widely used drugs worldwide as first-line drugs for the treatment of hyperlipidemia and the prevention and treatment of cardiovascular diseases. Most of the side effects of statins are known to be mild, and mainly hepatotoxicity and various muscle symptoms are known. Recently, there have been studies on concerns about an increase in the incidence of diabetes after using statins, but it was found that the benefits sufficiently outweigh the risk of side effects. Therefore, the use of statins in the appropriate group should be actively performed, and it seems that the side effects can be prevented through close physical observation and appropriate examination.

Citations

Citations to this article as recorded by  
  • The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients
    Roxana Nartea, Brindusa Ilinca Mitoiu, Ioana Ghiorghiu
    Current Issues in Molecular Biology.2023; 45(4): 3146.     CrossRef
  • The effects of L-carnitine in reducing hepatotoxicity of statins in rats
    Doaa Ibrahim, Shahad Bader, Omar Bader
    Medicinski casopis.2023; 57(3): 59.     CrossRef
Original Article
Effects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
Cardiovasc Prev Pharmacother. 2022;4(1):42-55.   Published online January 20, 2022
DOI: https://doi.org/10.36011/cpp.2022.4.e3
  • 3,515 View
  • 45 Download
  • 2 Citations
Abstract PDFSupplementary Material
Background
Since a sedentary lifestyle is considered a modifiable risk factor for cardiovascular disease (CVD), physical activity (PA) is recommended for type 2 diabetes mellitus (T2DM) patients to prevent CVD. We investigated the association between different levels of PA and the risk for CVD and all-cause mortality in patients with T2DM using nationwide data.
Methods
We examined health examination data and claims records of 2,745,637 participants with T2DM at baseline from the Korean National Health Insurance Service who underwent health examinations between 2009 and 2012. We excluded subjects with a history of myocardial infarction or stroke. Each participant was asked to report their weekly PA levels according to three categories: vigorous, moderate, and walking. The incidence of CVD and death was analyzed until 2017.
Results
The risk of CVD was lower in regular exercisers than in nonexercisers after adjusting for confounding variables. A dose-response trend was evident in the association between the degree of PA and CVD risk. All categories of PA were inversely associated with CVD risk and mortality. The reduction in CVD risk and all-cause mortality was more profound in patients aged ≥65 years.
Conclusions
Augmenting PA might have positive effects on the prevention of CVD and all-cause death, especially in the elderly. The benefits of PA were consistently observed in various subgroups regardless of the presence of chronic conditions. Therefore, clinicians should encourage elderly patients with T2DM to increase their daily PA.

Citations

Citations to this article as recorded by  
  • Incentivised physical activity intervention promoting daily steps among university employees in the workplace through a team-based competition
    Ayazullah Safi, Sanjoy Deb, Adam Kelly, Matthew Cole, Natalie Walker, Mohammed Gulrez Zariwala
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Effect of physical activity on incident atrial fibrillation in individuals with varying duration of diabetes: a nationwide population study
    JungMin Choi, So‑Ryoung Lee, Eue-Keun Choi, Kyung-Yeon Lee, Hyo-Jeong Ahn, Soonil Kwon, Kyung‑Do Han, Seil Oh, Gregory Y. H. Lip
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
Special Articles
Tafamidis for Cardiac Transthyretin Amyloidosis
Darae Kim, Jin-Oh Choi, Eun-Seok Jeon
Cardiovasc Prev Pharmacother. 2021;3(1):1-9.   Published online January 31, 2021
DOI: https://doi.org/10.36011/cpp.2021.3.e1
  • 4,825 View
  • 73 Download
  • 2 Citations
Abstract PDF
Transthyretin amyloid (ATTR) cardiomyopathy is a progressive disease caused by the infiltration of ATTR fibrils in the myocardium. Although it is a rare disease, ATTR cardiomyopathy is an important cause of heart failure with preserved ejection fraction, and its incidence is increasing due to improved diagnostic imaging tools. There has been a breakthrough in the field of transthyretin amyloidosis, which opens a new therapeutic door for the patients. In this review, an overview of tafamidis therapy in ATTR cardiomyopathy with recent results from clinical trials will be discussed.

Citations

Citations to this article as recorded by  
  • A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis
    Monali B. Patil, Piyush Ghode, Prashant Joshi
    Mini-Reviews in Medicinal Chemistry.2024; 24(6): 571.     CrossRef
  • Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
    Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn
    Diagnostics.2022; 12(3): 627.     CrossRef
Basic Concepts of a Mendelian Randomization Approach
Tae-Hwa Go, Dae Ryong Kang
Cardiovasc Prev Pharmacother. 2020;2(1):24-30.   Published online January 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e3
  • 3,781 View
  • 114 Download
  • 2 Citations
Abstract PDF
The Mendelian Randomization (MR) approach is a method that enables causal inference in observational studies. There are 3 assumptions that must be satisfied to obtain suitable results: 1) The genetic variant is strongly associated with the exposure, 2) The genetic variant is independent of the outcome, given the exposure and all confounders (measured and unmeasured) of the exposure-outcome association, 3) The genetic variant is independent of factors (measured and unmeasured) that confound the exposure-outcome relationship. This analysis has been used increasingly since 2011, but many researchers still do not know how to perform MR. Here, we introduce the basic concepts, assumptions, and methods of MR analysis to enable better understanding of this approach.

Citations

Citations to this article as recorded by  
  • Alcohol consumption and risk of psoriasis: Results from observational and genetic analyses in more than 100,000 individuals from the Danish general population
    Alexander Jordan, Charlotte Näslund-Koch, Signe Vedel-Krogh, Stig Egil Bojesen, Lone Skov
    JAAD International.2024; 15: 197.     CrossRef
  • MR-GGI: accurate inference of gene–gene interactions using Mendelian randomization
    Wonseok Oh, Junghyun Jung, Jong Wha J. Joo
    BMC Bioinformatics.2024;[Epub]     CrossRef
Original Article
Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
Kwan Yong Lee, Dong Il Shin, Sung Ho Her, Seung Hwan Han, Youngkeun Ahn, Dong-Soo Kim, Dong-Ju Choi, Hyuck Moon Kwon, Hyeon-Cheol Gwon, Seung-Woon Rha, Sang-Ho Jo, Sung Cil Lim, Jun-Pyo Myong, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2019;1(1):30-42.   Published online July 31, 2019
DOI: https://doi.org/10.36011/cpp.2019.1.e4
Correction in: Cardiovasc Prev Pharmacother 2020;2(1):31
  • 3,204 View
  • 10 Download
  • 2 Citations
Abstract PDF
Background
The aim of this multi-center prospective registry study was to evaluate the clinical efficacy of low-dose aspirin in vasospastic angina (VA) patients for the prevention of future cardiovascular events.
Methods
A total of 1,717 patients with positive and intermediate results of an intracoronary ergonovine provocation test in the VA in Korea registry (n=2,960) were classified into 100 mg/day aspirin intake (aspirin, n=743) and no-aspirin intake (control, n=974) groups. The primary end-point was a composite of major adverse cardiac events (MACEs) including cardiac death, new-onset arrhythmia, and acute coronary syndrome.
Results
The median follow-up duration was 2.0 years (25–75th, interquartile range 0.9–3.0 years). Cumulative composite MACE in the propensity score matched-pair cohort (n=1,028) was 3.6%. There was no significant difference in composite MACE between the aspirin and control groups (3.1% vs. 4.1%; hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.61–2.26; p=0.623). A sensitivity analysis of only the VA-positive population showed these results to be consistent. Even for patients with minimal organic stenosis (n=369), aspirin usage was not related to the incidence of a composite MACE (HR, 1.61; 95% CI, 0.55–4.72; p=0.380).
Conclusions
Low-dose aspirin does not protect against future cardiovascular events in VA patients, even patients who combine with minimal coronary artery stenosis.

Citations

Citations to this article as recorded by  
  • Characteristics of Patients with Vasospastic Angina in Korea: Data from a Large Cohort (VA-KOREA)
    Sung Eun Kim, Sang-Ho Jo, Won-Woo Seo, Min-Ho Lee, Hyun-Jin Kim, Seong-Sik Cho, Kwan Yong Lee, Dong-Soo Kim, Tae-Hyun Yang, Sung-Ho Her, Seung Hwan Han, Byoung-Kwon Lee, Youngkeun Ahn, Seung-Woon Rha, Hyeon-Cheol Gwon, Dong-Ju Choi, Sang Hong Baek
    Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 47.     CrossRef
  • Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
    Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
    Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1.     CrossRef
Review Articles
Challenges and Future in Precision Cardiovascular Medicine
Sang Hong Baek
Cardiovasc Prev Pharmacother. 2019;1(1):10-18.   Published online July 31, 2019
DOI: https://doi.org/10.36011/cpp.2019.1.e3
  • 5,152 View
  • 21 Download
  • 2 Citations
Abstract PDF
Cardiovascular disease (CVD) still remains the global leading cause of mortality and also impose major burdens on morbidity, quality of life, and societal costs despite of the remarkable progress of cardiovascular (CV) treatment over the past 50 years. CVD therapy improves CV outcomes in less than half of patients. Precision medicine is an attractive and advancing strategy to enhance for disease prevention, diagnosis, and tailored treatment and allocate limited resources more wisely and effectively. We are now in the middle of fourth industrial revolution by a robust confluence of biotechnology, physical science and information technologies. This approach is in its premature so far, but has begun to yield useful information that moves from the conventional ‘average response’ approach to more specific and targeted approaches governed by individual variability. This review aims to how precision medicine, genomics, and epigenetics work together to create a new era of CV precision medicine.

Citations

Citations to this article as recorded by  
  • Cell-free DNA in maternal blood and artificial intelligence: accurate prenatal detection of fetal congenital heart defects
    Ray Bahado-Singh, Perry Friedman, Ciara Talbot, Buket Aydas, Siddesh Southekal, Nitish K. Mishra, Chittibabu Guda, Ali Yilmaz, Uppala Radhakrishna, Sangeetha Vishweswaraiah
    American Journal of Obstetrics and Gynecology.2023; 228(1): 76.e1.     CrossRef
  • Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
    Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
    Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1.     CrossRef
Calcium channel blockers for hypertension: old, but still useful
Eun Mi Lee
Cardiovasc Prev Pharmacother. 2023;5(4):113-125.   Published online October 30, 2023
DOI: https://doi.org/10.36011/cpp.2023.5.e16
  • 4,268 View
  • 314 Download
  • 1 Citations
Abstract PDF
Calcium channel blockers (CCBs) constitute a heterogeneous class of drugs that can be divided into dihydropyridines (DHPs) and non-DHPs. DHP-CCBs are subcategorized into four generations based on the duration of activity and pharmacokinetics, while non-DHP-CCBs are subcategorized into phenylethylamine and benzodiazepine derivatives. DHP-CCBs are vascular-selective and function as potent vasodilators, whereas non-DHP-CCBs are cardiac-selective and are useful for treating tachyarrhythmia, but reduce cardiac contractility and heart rate. Traditional DHP-CCBs (nifedipine) mainly block L-type calcium channels, whereas novel CCBs block N-type (amlodipine) and/or T-type channels (efonidipine) in addition to L-type channels, leading to organ-protective effects. DHP-CCBs have a potent blood pressure–lowering effect and suppress atherosclerosis and coronary vasospasm. Diltiazem, a non-DHP-CCB, is highly effective for vasospasm control. CCBs reduce left ventricular hypertrophy and arterial stiffness. Amlodipine, a DHP-CCB, reduces blood pressure variability. L/N- and L/T-type CCBs combined with renin-angiotensin system blockers reduce proteinuria and improve kidney function compared with L-type CCBs. According to large-scale trials, DHP-CCBs reduce cardiovascular events in patients with isolated systolic hypertension, as well as in elderly and high-risk patients. Accordingly, CCBs are indicated for hypertension in elderly patients, isolated systolic hypertension, angina pectoris, and coronary vasospasm. Non-DHP-CCBs are contraindicated in high-grade heart block, bradycardia (<60 beats per minute [bpm]), and heart failure with reduced ejection fraction (HFrEF). DHP-CCBs should be used with caution in patients with tachyarrhythmia, HFrEF, and severe leg edema, and non-DHP-CCBs should be used carefully in those with constipation. Each CCB has distinct pharmacokinetics and side effects, underscoring the need for meticulous consideration in clinical practice.

Citations

Citations to this article as recorded by  
  • Design of Experimental Approach for Development of Rapid High Performance Liquid Chromatographic Process for Simultaneous Estimation of Metoprolol, Telmisartan, and Amlodipine from Formulation: Greenness and Whiteness Evaluation
    Mahesh Attimarad, Mohammed Jassim Alali, Hussain Ali Alali, Dana Hisham Alabdulmuhsin, Aljohara Khalid Alnajdi, Katharigatta Narayanaswamy Venugopala, Anroop B. Nair
    Molecules.2024; 29(5): 1087.     CrossRef
COVID-19 vaccination–related cardiovascular complications
Jae Yeong Cho, Kye Hun Kim
Cardiovasc Prev Pharmacother. 2023;5(4):134-143.   Published online October 27, 2023
DOI: https://doi.org/10.36011/cpp.2023.5.e17
  • 1,000 View
  • 23 Download
  • 1 Citations
Abstract PDF
The global response to the COVID-19 pandemic has led to rapid vaccine development and distribution. As vaccination efforts continue, concerns have arisen regarding potential adverse events associated with COVID-19 vaccination. This article examines emerging evidence on adverse events, including myocarditis, pericarditis, and thrombotic complications, in relation to COVID-19 vaccination. Reports of myocarditis and pericarditis cases following messenger RNA vaccines have sparked interest, with discussions revolving around potential mechanisms and genetic predispositions. The contrasting findings on pericarditis risk postvaccination highlight the complexity of studying this phenomenon. Thrombotic events, particularly vaccine-induced thrombotic thrombocytopenia, have garnered attention, prompting investigations into antibody responses and mechanisms. This article underscores the importance of ongoing research, collaboration, and data analysis for accurately understanding adverse events. While the COVID-19 vaccination campaign may have ended, it is still vital to maintain vigilance, collect comprehensive data and foster interdisciplinary collaboration to uphold vaccine safety and steer public health strategies in the upcoming period.

Citations

Citations to this article as recorded by  
  • The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era
    Kye Hun Kim
    Journal of Lipid and Atherosclerosis.2024; 13(1): 21.     CrossRef
Original Article
Changes in cardiovascular-related health behaviors during the COVID-19 pandemic
Eunji Kim, Chan-Hee Jung, Dae Jung Kim, Seung-Hyun Ko, Hae-Young Lee, Kyung-Yul Lee, Dae Ryong Kang, Sung Kee Ryu, Won-Young Lee, Eun-Jung Rhee, Hyeon Chang Kim
Cardiovasc Prev Pharmacother. 2023;5(1):15-23.   Published online January 27, 2023
DOI: https://doi.org/10.36011/cpp.2023.5.e2
  • 2,098 View
  • 44 Download
  • 1 Citations
Abstract PDFSupplementary Material
Background
The COVID-19 pandemic has been the most pressing health challenge in recent years. Meanwhile, prevention for other diseases, such as cardiovascular disease (CVD) has been less prioritized during the pandemic. COVID-19, a novel infectious disease, both had a direct impact on public health and provoked changes in health-related behaviors, including those for CVD prevention. This study sought to examine changes in CVD-related health behaviors during the COVID-19 pandemic and related sociodemographic factors.
Methods
We used data from the Cardiovascular Disease Prevention Awareness Survey conducted in Korea in June 2022. A total of 2,000 adults across Korea’s 17 provinces completed a structured questionnaire online or on a mobile device. Self-reported changes in CVD-related health behaviors were investigated. We used unadjusted and adjusted logistic regression models to explore the associations between negative changes and sociodemographic factors.
Results
In smoking, drinking, and healthcare service use, the proportion of those with positive changes surpassed the proportion of respondents who reported negative changes. In contrast, negative changes predominated for diet, exercise, and stress. Most individuals (52.6%) reported a deterioration of psychological distress. These negative changes were significantly associated with age, sex, marital status, and the presence of cardiometabolic disease.
Conclusions
The COVID-19 pandemic has affected CVD-related health behaviors. Based on these changes, CVD prevention should be encouraged with appropriate and prioritized strategies.

Citations

Citations to this article as recorded by  
  • Cardiovascular-related health behavior changes: lessons from the COVID-19 pandemic and post-pandemic challenges
    Inha Jung, Won-Young Lee
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(4): 99.     CrossRef
Review Article
Blood pressure control in hypertensive disorders of pregnancy
Helsi Rismiati, Hae-Young Lee
Cardiovasc Prev Pharmacother. 2022;4(3):99-105.   Published online July 29, 2022
DOI: https://doi.org/10.36011/cpp.2022.4.e16
  • 3,605 View
  • 156 Download
  • 1 Citations
Abstract PDF
Hypertension is a major cause of maternal morbidity and occurs as a complication in up to one in ten pregnancies. Hypertensive disorders of pregnancy encompass gestational hypertension, preeclampsia, chronic hypertension, and chronic hypertension with superimposed preeclampsia. However, the management of hypertensive disorders of pregnancy remains a matter of debate, particularly the blood pressure thresholds and targets for managing hypertension in pregnancy. Previously, there was no clear evidence of the effectiveness of aggressive blood pressure control in pregnancy due to the risk of fetal growth restriction. Recent clinical trials have shown that aggressive control of blood pressure in pregnant women is safe for both the mother and fetus. The purpose of this paper is to present a clinically oriented guide to the drugs of choice in patients with hypertension during pregnancy, present contrasts among different guidelines and recent clinical trials, and discuss the blood pressure thresholds and targets for hypertension during pregnancy based on recent studies.

Citations

Citations to this article as recorded by  
  • Combined Effects of Methyldopa and Baicalein or Scutellaria baicalensis Roots Extract on Blood Pressure, Heart Rate, and Expression of Inflammatory and Vascular Disease-Related Factors in Spontaneously Hypertensive Pregnant Rats
    Michał Szulc, Radosław Kujawski, Przemysław Ł. Mikołajczak, Anna Bogacz, Marlena Wolek, Aleksandra Górska, Kamila Czora-Poczwardowska, Marcin Ożarowski, Agnieszka Gryszczyńska, Justyna Baraniak, Małgorzata Kania-Dobrowolska, Artur Adamczak, Ewa Iwańczyk-S
    Pharmaceuticals.2022; 15(11): 1342.     CrossRef
Original Article
Development of a predictive model for the side effects of liraglutide
Jiyoung Min, Jiwon Shinn, Hun-Sung Kim
Cardiovasc Prev Pharmacother. 2022;4(2):87-93.   Published online April 27, 2022
DOI: https://doi.org/10.36011/cpp.2022.4.e12
  • 3,782 View
  • 39 Download
  • 1 Citations
Abstract PDFSupplementary Material
Background
Liraglutide, a drug used for the management of obesity, has many known side effects. In this study, we developed a predictive model for the occurrence of liraglutide-related side effects using data from electronic medical records (EMRs).
Methods
This study included 237 patients from Seoul St. Mary's Hospital and Eunpyeong St. Mary's Hospital who were prescribed liraglutide. An endocrinologist obtained medical data through an EMR chart review. Model performance was evaluated using the mean of the area under the receiver operating characteristic curve (AUROC) with a 95% confidence interval (CI).
Results
A predictive model was developed for patients who were prescribed liraglutide. However, 37.1% to 75.5% of many variables were missing, and the AUROC of the developed predictive model was 0.630 (95% CI, 0.551–0.708). Patients who had previously taken antiobesity medication had significantly fewer side effects than those without previous antiobesity medication use (20.7% vs. 41.4%, P<0.003). The risk of side effect occurrence was significantly higher in patients with diabetes than in patients without diabetes by 2.389 times (odds ratio, 2.389; 95% CI, 1.115–5.174).
Conclusions
This study did not successfully develop a predictive model for liraglutide-related side effects, primarily due to issues related to missing data. When prescribing antiobesity drugs, detailed records and basic blood tests are expected to be essential. Further large-scale studies on liraglutide-related side effects are needed after obtaining high-quality data.

Citations

Citations to this article as recorded by  
  • The effects and side effects of liraglutide as a treatment for obesity
    Jeonghoon Ha, Jin Yu, Joonyub Lee, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2022; 4(4): 142.     CrossRef
Review Article
Targets for rescue from fatty acid-induced lipotoxicity in pancreatic beta cells
Seok-Woo Hong, Won-Young Lee
Cardiovasc Prev Pharmacother. 2022;4(2):57-62.   Published online April 26, 2022
DOI: https://doi.org/10.36011/cpp.2022.4.e9
  • 2,071 View
  • 45 Download
  • 1 Citations
Abstract PDF
A persistent intake of excess calories increases plasma levels of free fatty acids, particularly the saturated form that has been shown to exert toxic effects on pancreatic beta cells by inducing dysfunction and apoptosis (i.e., lipotoxicity). An insufficient supply of insulin due to beta cell failure is a major factor in the onset and progression of type 2 diabetes; therefore, it is crucial to understand the cellular mechanisms of lipotoxicity to prevent beta cell failure. Many studies on the effects of lipotoxicity have demonstrated the various factors responsible for beta cell impairment, but the mechanisms of dysfunction and apoptosis resulting from lipotoxicity have not been fully described. This review discusses lipotoxicity-induced alterations of cellular mechanisms, and assesses drugs such as incretin mimetics, thiazolidinedione, and clusterin. Understanding the molecular mechanisms of lipotoxicity-induced beta cell failure is useful in guiding the development of new therapeutic targets for diabetes treatment.

Citations

Citations to this article as recorded by  
  • ВПЛИВ ПОЛІВІТАМІННОГО КОМПЛЕКСУ НА СТАН ПІДШЛУНКОВОЇ ЗАЛОЗИ ХОМ’ЯКІВ ЗА УМОВ ЕКСПЕРИМЕНТАЛЬНОГО МЕТАБОЛІЧНОГО СИНДРОМУ
    Н. Ю. Духніч, К. О. Калько, О. Я. Міщенко
    Medical and Clinical Chemistry.2023; (3): 72.     CrossRef

CPP : Cardiovascular Prevention and Pharmacotherapy